Navigation Links
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
Date:5/10/2013

INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies.

"We are disappointed in the results that we're announcing today," said Richard Gaynor , M.D., vice president, product development and medical affairs for Lilly Oncology.  "However, our oncology pipeline is still one of the most robust across the industry containing more than 20 molecules, including two Phase III molecules in five different tumor types."

Lilly plans to present data from this study at an upcoming scientific meeting.

Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30 million. The company's previously-issued financial guidance for 2013 remains unchanged.

About the Study
Patients enrolled in PRELUDE had histologically confirmed DLBCL with an International Prognostic Index (IPI) score of three to five at diagnosis. The IPI is a simple, clinical tool that is used to predict survival outcomes for patients with DLBCL. Patients enrolled also achieved a complete response or complete response-unconfirmed to cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab (R-CHOP) therapy. Patients were randomized in a 2:1 fashion to receive enzastaurin or placebo.

Treatment continued until patients developed progres
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
2. Lilly Declares Second-Quarter 2013 Dividend
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
5. Lilly Diabetes and Disney Publishing Worldwide Expand Collaboration
6. Lilly Celebrates National Volunteer Week with Deployment of Global Service Teams
7. Lilly Again Named One of DiversityIncs Top 50 Companies for Diversity
8. Lilly Reports First-Quarter 2013 Results
9. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
10. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- BRH Medical, Ltd., today announced that ... Application (510k) with the US Food and Drug Administration ... expects feedback from the FDA during the next quarter ... FDA pre-market clearance. Additional pre-market regulatory filings are anticipated ... for BRH Medical, commented, "We are thrilled to have ...
(Date:4/27/2015)... , April 27, 2015 TWi ... entered into a Settlement Agreement with Takeda Pharmaceutical ... , Inc., Takeda Pharmaceuticals America, Inc. (individually and ... patent litigation related to TWi,s generic dexlansoprazole delayed ... and 60 mg dosage strengths. An Abbreviated New Drug ...
(Date:4/24/2015)... NASHUA, New Hampshire , und ... 2015 (Stand Nr. 4410) iCAD, ... führender Anbieter von moderner Bildanalyse, Lösungen für ... Behandlung von Krebserkrankungen, hat heute die sofortige ... ® Electronic Brachytherapy (eBx ® ) ...
Breaking Medicine Technology:BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 4Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 5Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 6
... March 15, 2011 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation, bleeding and disorders ... for the fourth quarter and year ended December 31, ... for the three months ended December 31, 2010 were ...
... Pharmacy Benefit Consulting, the nation,s leading Pharmacy Benefit ... their clients. On February 16th, ARMSRx ... Lumber.  It was recommended and modeled by ARMSRx last ... making some simple changes.  The results speak for themselves. ...
Cached Medicine Technology:Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 2Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 3Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 4Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 5Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 6ARMSRx and 84 Lumber Hammer Down Rx Costs...Again 2
(Date:4/27/2015)... April 27, 2015 Array Health ... technology, has announced that Lance Hood, senior director of ... fourth annual Direct-to-Consumer Health Care Marketing Summit ... David Smith, Partner and Director of Payer Services, Leavitt ... care consumerism – through a retail/e-commerce perspective – and ...
(Date:4/27/2015)... April 27, 2015 Ticket Down is a ... Philadelphia for his upcoming concert on Sunday, June 21st. ... thrill his countless North American fans again in 2015 when ... his "Out There" tour. He will be performing in ... to listen to this legendary performer for the first time ...
(Date:4/27/2015)... Thanks to a $7.5 million grant ... half-dozen institutions, including American University, will operate in a ... and behavioral research aimed at ending the AIDS epidemic. ... with HIV or AIDS, according to the latest statistics. ... population over the age of 13 was living with ...
(Date:4/27/2015)... Angeles, CA (PRWEB) April 27, 2015 The ... has been to connect clients of personal injury attorneys with ... network of doctors has seen steady growth throughout their history ... Charles E. Richardson, DC and his team in the ... including a medical doctor and massage therapist, patients can find ...
(Date:4/27/2015)... April 27, 2015 Sitting or standing for ... and feel tired, and for those whose occupation requires them ... and taxi cab drivers, or to be on their feet ... the discomfort can be more severe and longer lasting. These ... syndrome. Dr. Madaiah Revana of Northeast Houston Vein Center is ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Paul McCartney Presale Tickets at Wells Fargo Center in Philadelphia: Ticket Down Slashes Paul McCartney Ticket Prices in Philadelphia at the Wells Fargo Center 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3
... Feb. 26 AIDS Action congratulates Jeffrey Crowley, an ... health care and HIV/AIDS for his appointment as Director ... He joins a well-respected and dedicated team in the ... and reports to Director Melody Barnes who has a ...
... inhibit both normal and virulent strains, study finds ... Combination treatment with two FDA-approved drugs shows promise ... study shows. , In laboratory tests, researchers at ... National Institute of Allergy and Infectious Diseases found ...
... The number of Americans traveling abroad for healthcare is ... trend as the recession worsens and more Americans are left ... to the Deloitte Centre for Health Solutions, the number of ... million in 2010 and 15.75 million by 2017. The $16 ...
... Ignagni, President and CEO of America,s Health Insurance Plans, ... President,s budget:"Today,s budget submission sends a signal to the ... health care. We applaud the President for laying ... to put our nation on a path towards comprehensive ...
... Consultancy, is pleased to announce the launch of a further nine ... listings to relevant specialist industries. , ... (PRWEB) February ... & Marketing Consultancy , is pleased to announce the launch of ...
... RALEIGH, N.C., Feb. 26 Arbor Pharmaceuticals, a ... that the company has launched XYLAREX - a ... otitis media (middle ear,infections). XYLAREX is a ... reduce the number of ear infections children experience. ...
Cached Medicine News:Health News:AIDS Action Applauds President on Appointment of Jeffrey Crowley as Director of National AIDS Policy 2Health News:Antibiotic Combo Fights Resistant TB 2Health News:Americans Will Soon Have Medical Butlers to Assist in Medical Tourism Research 2Health News:AHIP Statement on the President's Budget 2Health News:Simply Marcomms Launch New Specialist Online Industry Directories 2Health News:Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children 2
... System is the smallest and lightest continuous ... market. It is designed to help active ... complying with therapy. The GoodKnight 420S model ... usage data. It also detects persistent residual ...
Chase micro-hemocrit tubes are manufactured from soda lime glass, packed in plastic vials with reclosable snap-lock caps to maintain cleanliness....
Hemato-clad Hematocrit Tubes combine the precision of glass with the safety provided by a Mylar® overwrap. Now you can give your laboratory staff safety with no compromise in accuracy....
... help protect healthcare workers from accidental injury ... procedures. Each BD plastic-coated micro-hematocrit is encased ... that it does not interfere with the ... the sample. The mylar film will keep ...
Medicine Products: